| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Y.B Urban Renewal - Residential Development Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪15.61 |
| 52 Week High | ₪20.75 |
| 52 Week Low | ₪2.91 |
| Beta | 0.15 |
| 11 Month Change | -15.62% |
| 3 Month Change | -8.77% |
| 1 Year Change | 291.23% |
| 33 Year Change | -74.03% |
| 5 Year Change | -87.42% |
| Change since IPO | -94.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| YBRD | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | -7.4% | 9.2% | 2.7% |
| 1Y | 291.2% | -2.5% | 3.7% |
Return vs Industry: YBRD exceeded the IL Pharmaceuticals industry which returned -1.2% over the past year.
Return vs Market: YBRD exceeded the IL Market which returned 3.5% over the past year.
Price Volatility
| YBRD volatility | |
|---|---|
| YBRD Average Weekly Movement | 13.6% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 7.3% |
| 10% least volatile stocks in IL Market | 3.2% |
Stable Share Price: YBRD's share price has been volatile over the past 3 months.
Volatility Over Time: YBRD's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 2 | Evyatar Cohen | cannassure.life |
Y.B Urban Renewal - Residential Development Ltd engages in the cultivation and production of medical cannabis. Its products comprise medical cannabis oils, indoor inflorescences, select inflorescences, value inflorescences, and cannavix. The company was formerly known as Cannassure Therapeutics Ltd and changed its name to Y.B Urban Renewal - Residential Development Ltd in July 2024.
Y.B Urban Renewal - Residential Development Ltd Fundamentals Summary
| YBRD fundamental statistics | |
|---|---|
| Market cap | ₪47.69m |
| Earnings (TTM) | -₪1.79m |
| Revenue (TTM) | ₪11.00m |
4.3x
P/S Ratio-26.7x
P/E RatioIs YBRD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YBRD income statement (TTM) | |
|---|---|
| Revenue | ₪11.00m |
| Cost of Revenue | ₪7.69m |
| Gross Profit | ₪3.31m |
| Other Expenses | ₪5.09m |
| Earnings | -₪1.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 30.05% |
| Net Profit Margin | -16.24% |
| Debt/Equity Ratio | -66.0% |
How did YBRD perform over the long term?
See historical performance and comparison